NCT00246987

A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 341 (planned)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To determine the effect on glycemic control and lipid parameters of the 2.5 and 5 mg. doses of BMS-298585 in drug naive subjects with Type 2 diabetes as an adjunct to diet and exercise.

Conditions

• Diabetes, Type 2

Interventions

Type	Name	Description
DRUG	Muraglitazar

Timeline

• Start date: 2003-06-01
• Completion: 2004-04-01
• First posted: 2005-11-01
• Last updated: 2012-04-27

Locations

130 sites across 7 countries: United States, Australia, Canada, Mexico, Poland, Puerto Rico, Taiwan